Connect Biopharma Holdings Investor Relations Material

Connect Biopharma Holdings Ltd is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases by leveraging its expertise in T cell biology. The company is advancing a pipeline of novel small molecules and biologics, targeting various conditions such as atopic dermatitis, ulcerative colitis, and chronic pruritus. These therapies aim to address significant unmet medical needs by modulating immune system responses. Connect Biopharma's approach combines a deep understanding of T cell-driven research with proprietary Immune Modulation Technology Platform, aiming to significantly reduce the discovery time and cost for new, effective treatments. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.